Ludwig Institute for Cancer Research Limited

Medimmune Limited

Smithkline Beecham Biologicals S.a.

Departemente D'immunologie Institut Henri Beaufour

Department D'immunologie Institut Henri Beaufour

Catherine Uyttenhove

Jacques Van Snick

Thierry Boon

Richard John Simpson

Catherine Druez

Jean-Christophe Renauld

Pierre G Coulie

Pierre Braquet

Bernard Dugas

Jean M Mencia-Huerta

William Dall'Acqua

Jennifer Lynne Reed

Silvia Silla

Jochen Moeller

Francoise Cormont

Lothar Hultner

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-3) are provided, particularly recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Particular antibodies are provided which specifically recognize and neutralize TGF-β3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17 and MTGF-β3-19, whose sequences are provided herein.

TGF-β3 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

TGF-β1 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-&#x3b2;3) are provided, particularly recognizing human and mouse TGF-&#x3b2;3, particularly antibodies and fragments that do not recognize or bind TGF-&#x3b2;1 or TGF-&#x3b2;2. Particular antibodies are provided which specifically recognize and neutralize TGF-&#x3b2;3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-&#x3b2;3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-&#x3b2;3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-&#x3b2;3-9, MTGF-&#x3b2;3-12, MTGF-&#x3b2;3-16, MTGF-&#x3b2;3-17 and MTGF-&#x3b2;3-19, whose sequences are provided herein.

TGF-&#x3b2;3 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-&#x3b2;1) are provided, particularly recognizing human and mouse TGF-&#x3b2;1 and not recognizing or binding TGF-&#x3b2;2 or TGF-&#x3b2;3. Particular antibodies are provided which specifically recognize and neutralize TGF-&#x3b2;1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-&#x3b2;1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-&#x3b2;1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

TGF-&#xdf;1 specific antibodies and methods and uses thereof

TGF-&#x3b2;1 specific antibodies and methods and uses thereof

The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

Recombinant anti-interleukin-9 antibodies

The present invention pertains to improved adjuvant compositions comprising a mixture of a saponin adjuvant such as QS21 with monophosphoryl lipid A or derivative thereof such as 3D-MPL and interleukin 12. These compositions are useful in a range of prophylactic and therapeutic applications, particularly in vaccines, including cancer vaccines.

Adjuvant compositions for vaccines

The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells especially from murine and human sources and further which is capable of augmenting proliferation of IL3- or IL4-responsive cells. Even more particularly, the present invention relates to the helper T cell growth factor P40, pharmaceutical compositions thereof, antibodies thereto and recombinant DNA clones thereof. The present invention also contemplates a method for inducing the proliferation of helper T cells as well as IL3- and Il4-responsive cells. The helper T cells growth factor contemplated herein is useful in the stimulation of specific cells in the immune system, either alone or in combination with IL3 or IL4.

Process for preparing mammalian T cell growth factor P40

T cell growth factor

A method for inhibiting production of IgE, and a method for enhancing production of IgG are taught. The methods are linked to the role of interleukin 9 in antibody production. Specifically, production of IgG is potentiated by administering either to a subject or a cell culture a combination of interleukin 4 and interleukin 9. Production of IgE is inhibited by administering an amount of an interleukin 9 inhibitor to a subject.

Method for inhibiting production of IgE by using IL-9 inhibitors

The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells. Even more particularly, the present invention relates to the helper T cell growth factor P40, pharmaceutical compositions thereof and antibodies thereto. The present invention also contemplates a method for inducing the proliferation of helper T cells. The helper T cell growth factor contemplated herein is useful in the stimulation of specific cells in the immune system.

T cell growth factor glycoproteins

The invention relates to substantially pure interleukin 9 receptor molecules and the use thereof. The uses include use as an interleukin-9 inhibitor, as a diagnostic agent for determining interleukin-9, and as a screening agent for pharmaceuticals. The interleukin-9 receptor is characterized as a glycoprotein of about 64 kilodaltons which, upon digestion with N-glycosidase F, yields a peptide of about 54 kilodaltons.

Uses of substantially pure interleukin-9 receptor

The glycoprotein known as P40, characterized by a molecular weight of from about 30 to 40 kilodaltons and an isoelectric point of about 10, previously recognized as a helper T cell growth factor, also enhances growth and proliferation of mast cells and their maintenance viability and differentation status in vitro.

Growing community of inventors

Brussels, Belgium

Catherine Uyttenhove